A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.
Phase 4
Completed
- Conditions
- Diabetic Peripheral Angiopathy
- Interventions
- Drug: Renexin CR 200/160mg
- Registration Number
- NCT05906199
- Lead Sponsor
- SK Chemicals Co., Ltd.
- Brief Summary
This study is to compare and evaluate the effect of improving the carotid IMT and lipid level of the Cilostazol/Ginkgo leaf extract group with the aspirin administrated group in patients with diabetic peripheral angiopathy.
- Detailed Description
A Prospective, Randomized, Active-controlled, Parallel, Open, Multi-center, Phase IV
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 105
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Renexin CR 200/160mg Renexin CR 200/160mg Single oral administration of Renexin CR 200/160mg, QD Aspirin 100mg Aspirin 100mg Single oral administration of Aspirin 100mg, QD
- Primary Outcome Measures
Name Time Method Changes in carotid IMT 24weeks, 48weeks Changes in carotid IMT after 24weeks, 48weeks of administration compared to before administration of investigational product
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
SKChemicals
🇰🇷Seongnam, Gyunggi-do, Korea, Republic of
SK chemicals
🇰🇷Seoul, Korea, Republic of